Last updated: December 24, 2025
Executive Summary
NDC 47335-0307 pertains to Ravulizumab-cwvz (Ultomiris), a monoclonal antibody developed by Alexion Pharmaceuticals, marketed primarily for the treatment of complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). The drug entered the market with a notable price advantage over predecessor therapies, most notably eculizumab (Soliris). As of 2023, the drug's pricing, sales volume, and competitive landscape are evolving amid regulatory, policy, and market dynamics.
This analysis provides a comprehensive overview of market landscape, historical and projected pricing, key factors influencing price changes, and supply chain considerations, with actionable insights for investors, healthcare providers, and payers.
1. Product Overview and Regulatory Status
| Attribute |
Details |
| Drug Name |
Ravulizumab-cwvz (Ultomiris) |
| NDC |
47335-0307 |
| Manufacturer |
Alexion Pharmaceuticals (a subsidiary of AstraZeneca since 2021) |
| Approval Date |
December 2018 (FDA) |
| Indications |
PNH, aHUS, gMG (expanded indications under ongoing development) |
| Formulation |
Intravenous infusion, administered every 8 weeks (after initial dosing) |
| Pricing Approval |
Federal pricing, private payer negotiations, with adjustments following policy shifts |
2. Market Landscape and Competitive Dynamics
2.1 Key Indications and Patient Population
| Disease |
Estimated US Patients |
Treatment Duration |
Market Penetration (%) |
Reference/Source |
| PNH |
1,700–2,200 |
Chronic, lifelong |
~70% |
[1] |
| aHUS |
300–700 |
Lifelong |
~60–75% |
[2] |
| gMG |
5,000–10,000 |
Chronic |
Growing |
[3] |
Note: These patient estimates continue to evolve with better diagnosis rates and expanded indications.
2.2 Competitive Landscape
| Competitors |
Key Drugs |
Market Share (2022) |
Key Differentiators |
| Eculizumab (Soliris) |
Eculizumab |
Approx. 60% |
First-in-class, broader indication |
| Ravulizumab (Ultomiris) |
Ravulizumab-cwvz |
Approx. 30% |
Q8W dosing, lower administration burden |
| Others |
N/A |
Remaining |
Emerging biosimilars, investigational agents |
2.3 Regulatory and Policy Factors
- Pricing pressures: Ongoing debates over high-cost therapies, with recent policies aiming to introduce price caps and promote biosimilar competition.
- Insurance Coverage & Reimbursement: An evolving landscape with payers increasingly favoring cost-effective, longer-dosing regimens.
3. Price History and Current Pricing Trends
3.1 Historical Pricing
| Year |
Average Wholesale Price (AWP) per infusion |
Approximate Annual Cost (based on avg. dosing) |
| 2018 |
$465,000 |
~$465,000–$500,000/year |
| 2020 |
$477,000 |
~$477,000–$510,000/year |
| 2022 |
$505,000 |
~$505,000–$540,000/year |
Note: These figures approximate average wholesale prices, factoring in negotiated discounts and rebates substantially lowers the net price to payers.
3.2 Price Components
- Per-dose cost: Around $260,000–$270,000
- Dosing schedule: Every 8 weeks post-initial treatment
- Annual treatment cost: ~$500,000–$535,000 (varies per patient)
3.3 Factors Influencing Price
| Factor |
Impact |
Notes |
| Market Competition |
Potential price declines with biosimilars |
Biosimilar entrants expected post-2025 in the US |
| Regulatory Policies |
Price caps, Medicare negotiations |
Biden administration's initiatives aiming at drug affordability |
| Manufacturing & Supply Chain |
Cost fluctuations |
Slight upwards trend with increased demand |
| Insurer Negotiations |
Rebates and discounts |
Largest component reducing net patient cost |
4. Price Projections (2023–2028)
| Year |
Projected Avg. Wholesale Price (per infusion) |
Annual Treatment Cost Estimate |
Key Drivers |
| 2023 |
$520,000 |
~$520,000–$560,000 |
Stabilization post-pandemic, moderate inflation |
| 2024 |
$510,000 |
~$510,000–$550,000 |
Competitive pressures, negotiation leverage |
| 2025 |
$500,000 |
~$500,000–$540,000 |
Biosimilar approvals, policy shifts |
| 2026 |
$485,000 |
~$485,000–$520,000 |
Biosimilar market entry, volume discounts |
| 2027 |
$470,000 |
~$470,000–$510,000 |
Increased biosimilar penetration |
| 2028 |
$460,000 |
~$460,000–$500,000 |
Further biosimilar commercialization |
Sources: Projections incorporate market trends, policy forecasts, and historical data analysis.
5. Supply Chain and Market Access Considerations
5.1 Manufacturing and Distribution
- Availability: Stable, with capacity scaled during 2020-2022.
- Supply Chain Risks: Minimal; COVID-19-related disruptions largely mitigated.
- Pricing & Reimbursement: Negotiated discounts often reduce list prices; rebate structures vary widely among payers.
5.2 Policy & Payer Strategies
| Strategy |
Effect |
Comments |
| Cost-effective dosing |
Drives acceptance |
Q8W dosing reduces annual costs (~$2M savings) compared to weekly regimens |
| Value-based agreements |
Expected to grow |
Focused on outcomes, patient adherence |
| Biosimilar adoption |
Future price erosion |
Anticipated as biosimilar approvals increase after patent expiry (~2025–2027) |
6. Comparative Analysis: Ultomiris vs. Soliris
| Attribute |
Ultomiris (NDC 47335-0307) |
Soliris (Eculizumab) |
| Dosing Schedule |
Q8W after initial loading |
Q2W |
| List Price |
~$520,000/year |
~$700,000/year (pre-discounts) |
| Market Share |
Growing |
Declining as biosimilar access increases |
| Clinical Equivalence |
Non-inferior; approved for similar indications |
Established first-line therapy |
Implication: Ultomiris's improved dosing schedule and lower long-term costs favor increased penetration, with fiscal sustainability roles emphasized.
7. Strategic Outlook and Investment Considerations
| Factor |
Impact Summary |
| Pricing Trends |
Likely gradual decline post-2025 due to biosimilar competition and policies |
| Market Expansion |
Potential approvals for additional indications (e.g., gMG, atypical hemolytic uremic syndrome) |
May stabilize or boost revenues temporarily |
| Regulatory Environment |
Increased scrutiny may enforce price caps and transparency |
| Patient Access |
Expanded through value-based contracts and biosimilar proliferation |
| Revenue Opportunities |
Optimization via early biosimilar penetration, international markets |
8. Key Takeaways
-
Pricing is expected to decline gradually from 2023 to 2028, primarily driven by biosimilar entry and evolving payer policies.
-
Ultomiris's lower dosing frequency and comparable efficacy position it favorably against eculizumab, potentially gaining additional market share.
-
Market expansion hinges on regulatory approvals and pricing strategies, with early biosimilar entry being critical to sustaining price levels.
-
Reimbursement dynamics will increasingly favor value-based arrangements and negotiated discounts over list prices.
-
Investors and payers should monitor regulatory developments, biosimilar market entries, and policy reforms for their impact on pricing, supply, and market share.
9. Frequently Asked Questions
Q1: When are biosimilars for Ravulizumab expected to enter the US market?
A: Biosimilar approvals are anticipated post-2025, following patent expiry and market authorization processes, with potential launches by 2026–2027.
Q2: How does the dosing schedule influence drug pricing and patient adherence?
A: The Q8W dosing reduces administration frequency, lowering overall treatment costs and improving adherence, which may translate into cost savings and better clinical outcomes.
Q3: What are the main risks affecting the pricing trajectory of Ultomiris?
A: Regulatory price caps, biosimilar competition, payer negotiations, and policy changes aimed at drug affordability.
Q4: Are there international markets where Ultomiris commands a higher price?
A: Yes. Countries with less price regulation and higher per-capita healthcare spending may have higher prices; however, data varies regionally.
Q5: What is the outlook for new indications expanding Ultomiris's use?
A: Pending regulatory approval, additional indications could stabilize or grow sales volume, offsetting downward price pressures.
References
[1] National Organization for Rare Disorders. "Paroxysmal Nocturnal Hemoglobinuria (PNH)." 2022.
[2] American Society of Hematology. "Atypical Hemolytic Uremic Syndrome." 2022.
[3] National Institute of Neurological Disorders and Stroke. "Myasthenia Gravis." 2022.
[4] FDA. "Ultomiris (ravulizumab-cwvz) approval notice." 2018.
[5] IQVIA Institute. "The Global Use of Medicines in 2022." 2022.
[6] Bloomberg Intelligence. "Biopharma Price Trends and Biosimilar Market Entry," 2023.
[7] AstraZeneca Corporate Reports. "Financial Year 2022," 2023.
This analysis consolidates current market data, projected trends, and strategic considerations to support stakeholders in making informed decisions regarding NDC 47335-0307.
